Skip to content
MarketNewsAPI
Live news Screener Coverage Pricing Docs REST API WebSocket API MCP server Company Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
CLYM$10.19-0.35(-3.32%)Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026[7:30:00 PM ET]TECK$59.05+0.15(+0.25%)Teck Provides Update on Highland Valley Copper Operations[3:18:56 PM ET]AXON$422.00+7.40(+1.78%)Axon Announces Body 5: Next-Generation Camera Built for the AI Era Axon (Nasdaq: AXON), the global leader in public safety technology, today announced Axon Body 5, its newest body-worn camera designed to bring more...[1:00:00 PM ET]PFE$30.02-0.40(-1.31%)Pfizer's 25-Valent Pediatric Pneumococcal Conjugate Vaccine Candidate Shows Robust Phase 2 Data at IDWeek 2026[11:18:00 AM ET]BIVI$1.24-0.04(-3.13%)From Private Credit to Fusion Power: New to The Street Show #777 Premieres Tonight on Bloomberg Television[10:30:00 AM ET]AMGN$439.26-8.02(-1.79%)IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER Amgen (NASDAQ:AMGN) today announced landmark interim Phase 3 results showing that IMDELLTRA® (tarlatamab-dlle) in combination with AstraZeneca's...[10:30:00 AM ET]JNJ$263.81-3.80(-1.42%)Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer Johnson & Johnson (NYSE: JNJ) today announced new results from the Phase 3 PROTEUS substudy that directly compared the investigational use of...[8:54:00 AM ET]PBLS$24.79-2.13(-7.91%)Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors[8:45:00 AM ET]SMTC$131.80+6.68(+5.34%)Semtech Brings 5G Network Slicing, FIPS 140-3 to IACP 2026[8:00:00 AM ET]GMAB$43.85+3.85(+9.63%)Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer[7:00:00 AM ET]INCY$115.00-1.93(-1.65%)Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer[7:00:00 AM ET]

RYDE · AMEX

Ryde Group Ltd.

$0.65 +0.01 (+2.26%)

Company overview

Ryde Group Ltd. engages in mobility and quick commerce businesses in Singapore. The Mobility segment provides carpooling and ride-hailing services. The Quick Commerce segment offers real-time on-demand, scheduled, and multi-stop parcel delivery services. The company was founded in 2014 and is headquartered in Singapore.

Sector
Technology
Industry
Software - Application
Exchange
AMEX
Market cap
$97.5M
Employees
30
Headquarters
Singapore
Website
rydesharing.com
CEO
Junming Zou
Listed
March 6, 2024
P/E
-0.78
Dividend yield
0.00%

Company financials

Revenue
$16.1M
Gross profit
-$3.6M
Operating income
-$10.9M
EBITDA
-$17.1M
Net income
-$19.8M
EPS
-$0.84
Total assets
$38.3M
Total debt
$59,000
Gross margin
-22.25%
Net margin
-122.39%
Earnings yield
-128.69%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

No geographic segmentation.

Showing FY 2025

Price chart

0.340.650.971.281.60
RYDE 1D AMEX O0.67H0.70L0.66C0.67+0.01 (+2.26%)Vol20.24K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
RYDE Legal Levi & Korsinsky Notifies Ryde Group Ltd (RYDE) Shareholders of Class Action Lawsuit and November 11, 2026 Deadline ACCESS Newswire
RYDE Legal Pomerantz LLP Issues Important Reminder to Investors in Ryde Group Ltd. of Class Action Lawsuit – RYDE ACCESS Newswire
RYDE Legal Ryde Group Ltd (RYDE) Lawsuit - Investors Urged to Contact Levi & Korsinsky Before November 11, 2026 ACCESS Newswire
RYDE Legal RYDE DEADLINE: Levi & Korsinsky Reminds Ryde Group Ltd Investors of Upcoming Securities Class Action Deadline ACCESS Newswire
RYDE Legal Securities Lawsuit Alert: Ryde Group Ltd (RYDE) - Contact Levi & Korsinsky Before November 11, 2026 ACCESS Newswire
RYDE Legal Pomerantz LLP Informs Shareholders of Securities Class Action Filing Against Ryde Group Ltd. – RYDE ACCESS Newswire
RYDE Press release Ryde Enters Into Term Sheet for Strategic Investment in OneT Solutions ACCESS Newswire
RYDE Legal November 9, 2026 Deadline Approaching: Join Class Action Against Ryde Group Ltd (RYDE) - Contact Levi & Korsinsky ACCESS Newswire
RYDE Legal Lost Money on Ryde Group Ltd (RYDE)? Join Class Action Before November 9, 2026 - Contact Levi & Korsinsky ACCESS Newswire
RYDE Legal Bronstein, Gewirtz & Grossman LLC Urges Ryde Group Ltd Investors to Act: Class Action Filed Alleging Investor Harm GlobeNewswire
RYDE Legal Recover Investment Losses: Class Action Initiated Against Ryde Group Ltd (RYDE) ACCESS Newswire
RYDE Legal RYDE Investors Have Opportunity to Lead Ryde Group Ltd. Securities Fraud Lawsuit with SBS Law GlobeNewswire
RYDE Legal RYDE DEADLINE: SueWallSt Reminds Ryde Group Ltd Investors of Upcoming Securities Class Action Deadline PRNewsWire
RYDE Legal Pomerantz LLP Issues Important Reminder to Investors in Ryde Group Ltd. of Class Action Filing – RYDE ACCESS Newswire
RYDE Legal Securities Fraud Class Action Filed Against Ryde Group Ltd (RYDE) - Levi & Korsinsky Reminds Investors of November 9, 2026 ACCESS Newswire
RYDE Legal RYDE Shareholder Alert: Ryde Group Ltd Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky Levi & Korsinsky, LLP encourages investors who suffered losses in Ryde Group Ltd (NYSE: RYDE) to contact the firm. PR Newswire
RYDE Legal Levi & Korsinsky Notifies Ryde Group Ltd (RYDE) Shareholders of Class Action Lawsuit and November 9, 2026 Deadline ACCESS Newswire
RYDE Legal Pomerantz LLP Informs Shareholders of Securities Class Action Against Ryde Group Ltd. – RYDE ACCESS Newswire
RYDE Legal RYDE Stock Drop - Robbins LLP Reminds Investors They May Be Eligible to Lead the Class Action Lawsuit Against Ryde Group Ltd Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons an. PR Newswire
RYDE Legal Join Class Action to Recover Losses from Ryde Group Ltd (RYDE) - Contact Levi & Korsinsky Before November 9, 2026 ACCESS Newswire
See more
FAQ

Questions about Ryde Group Ltd.

What does Ryde Group Ltd. do?
Ryde Group Ltd. engages in mobility and quick commerce businesses in Singapore. The Mobility segment provides carpooling and ride-hailing services. The Quick Commerce segment offers real-time on-demand, scheduled, and multi-stop parcel delivery services. The company was founded in 2014 and is headquartered in Singapore.
What is RYDE's market cap?
Ryde Group Ltd. (RYDE) is a listed stock with a live quote. The latest market cap on this page is $97.5M.
Where is Ryde Group Ltd. headquartered?
Ryde Group Ltd. is headquartered in Singapore.
How do I get RYDE news from the API?
Call GET /v1/news?tickers=RYDE. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does RYDE news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for RYDE, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the RYDE price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 2,000 REST requests a day. Paid Pro removes the daily cap. If you don't subscribe, the account stays on Free.

Start 7-day free trial Read the docs